Skip to main content
Top
Published in: Clinical Rheumatology 1/2017

01-01-2017 | Original Article

Clinical, biochemical, and radiological characterization of the calcinosis in a cohort of Mexican patients with systemic sclerosis

Authors: María Pilar Cruz-Domínguez, Grettel García-Collinot, Miguel A. Saavedra, Gabriela Medina, Rosa Angélica Carranza-Muleiro, Olga Lidia Vera-Lastra, Luis J. Jara

Published in: Clinical Rheumatology | Issue 1/2017

Login to get access

Abstract

Calcinosis is a frequent complication of systemic sclerosis (SSc) that is usually located in extremities but may occur across the board. The aim of our study was to identify and quantify the distribution of calcinosis in a cohort of Mexican patients with SSc and its association with clinical features and autoantibodies. A cohort of patients with SSc (2013 ACR/EULAR criteria), classified in diffuse cutaneous (dcSSc) and limited cutaneous (lcSSc) (Le Roy criteria), was studied. For their analysis, patients were allocated into those with and without calcinosis (clinical and/or radiological). The evaluation included the modified Rodnan scale for skin and Medsger disease severity scale (DSS). Calcium, phosphorus, vitamin D, and parathyroid hormone (PTH) and antinuclear antibodies and extractable nuclear antigens were determined in serum. A total of 109 patients were included, 41 (37 %) with and 68 (63 %) without calcinosis. Calcinosis was more frequent in patients with dcSSc (55 vs 27 %). In total, we identified 354 sites with calcinosis and mean per patient of 12.0 ± 9.1; the most common sites affected were the hands (83 %), proximal upper extremity (27 %), and proximal lower extremity (22 %). Patients with calcinosis had a higher score of Rodnan scale, Mesdger DSS, and frequency of anti-nucleolar and anti-Scl-70 antibodies compared to those without calcinosis. Abnormal PTH elevation was found in 35 % of patients with calcinosis and 23 % without it. The prevalence of calcinosis is high in Mexican patients with SSc, especially in diffuse variety, and is associated with increased severity of disease.
Literature
1.
go back to reference Boulman N, Slobodin G, Rozenbaum M, Rosner I (2005) Calcinosis in rheumatic diseases. Semin Artritis Rheum 34:805–812CrossRef Boulman N, Slobodin G, Rozenbaum M, Rosner I (2005) Calcinosis in rheumatic diseases. Semin Artritis Rheum 34:805–812CrossRef
2.
go back to reference Makol A, Ytterberg SR (2011) Images in clinical medicine. Calcinosis cutis in systemic sclerosis. N Engl J Med 364:2245CrossRefPubMed Makol A, Ytterberg SR (2011) Images in clinical medicine. Calcinosis cutis in systemic sclerosis. N Engl J Med 364:2245CrossRefPubMed
3.
go back to reference Davies C, Jeziorska M, Freemont AJ, Herrick AL (2006) Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis. Rheumatology (Oxford) 45:1349–1355CrossRef Davies C, Jeziorska M, Freemont AJ, Herrick AL (2006) Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis. Rheumatology (Oxford) 45:1349–1355CrossRef
4.
go back to reference Braun-Moscovici Y, Furst DE, Markovits D, Rozin A, Clements PJ, Nahir AM et al (2008) Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosis. J Rheumatol 35:2201–2205CrossRefPubMed Braun-Moscovici Y, Furst DE, Markovits D, Rozin A, Clements PJ, Nahir AM et al (2008) Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosis. J Rheumatol 35:2201–2205CrossRefPubMed
5.
go back to reference Vitiello M, Abuchar A, Santana N, Dehesa L, Kerdel F (2012) An update on the treatment of the cutaneous manifestations of systemic sclerosis. J Clin Aesthet Dermatol 5:33–43PubMedPubMedCentral Vitiello M, Abuchar A, Santana N, Dehesa L, Kerdel F (2012) An update on the treatment of the cutaneous manifestations of systemic sclerosis. J Clin Aesthet Dermatol 5:33–43PubMedPubMedCentral
6.
go back to reference Vacca A, Cormier C, Mathieu A, Kahan A, Allanore Y (2011) Vitamin D levels and potential impact in systemic sclerosis. Clin Exp Rheumatol 29:1024–1031PubMed Vacca A, Cormier C, Mathieu A, Kahan A, Allanore Y (2011) Vitamin D levels and potential impact in systemic sclerosis. Clin Exp Rheumatol 29:1024–1031PubMed
7.
go back to reference Caramaschi P, Dalla Gassa A, Ruzzenente O, Volpe A, Ravagnani V, Tinazzi I et al (2010) Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol 29:1419–1425CrossRefPubMed Caramaschi P, Dalla Gassa A, Ruzzenente O, Volpe A, Ravagnani V, Tinazzi I et al (2010) Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol 29:1419–1425CrossRefPubMed
8.
go back to reference Antico A, Tampoia M, Tozzoli R, Bizzaro N (2012) Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 12:127–136CrossRefPubMed Antico A, Tampoia M, Tozzoli R, Bizzaro N (2012) Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 12:127–136CrossRefPubMed
9.
10.
11.
go back to reference Valenzuela A, Chung L (2015) Calcinosis: pathophysiology and management. Curr Opin Rheumatol 27:542–548CrossRefPubMed Valenzuela A, Chung L (2015) Calcinosis: pathophysiology and management. Curr Opin Rheumatol 27:542–548CrossRefPubMed
12.
go back to reference Vayssairat M, Hidouche D, Abdoucheli-Baudot N, Gaitz JP (1998) Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression? Ann Rheum Dis 57:252–254CrossRefPubMedPubMedCentral Vayssairat M, Hidouche D, Abdoucheli-Baudot N, Gaitz JP (1998) Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression? Ann Rheum Dis 57:252–254CrossRefPubMedPubMedCentral
13.
go back to reference Sujau I, Ng CT, Sthaneshwar P, Sockalingam S, Cheah TE, Yahya F, Jasmin R (2015) Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort. Int J Rheum Dis 18:459–465CrossRefPubMed Sujau I, Ng CT, Sthaneshwar P, Sockalingam S, Cheah TE, Yahya F, Jasmin R (2015) Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort. Int J Rheum Dis 18:459–465CrossRefPubMed
14.
go back to reference Cambiaghi S, Imondi D, Gangi S, Vegni C (2000) Fingertip calcinosis cutis. Cutis 66:465–467PubMed Cambiaghi S, Imondi D, Gangi S, Vegni C (2000) Fingertip calcinosis cutis. Cutis 66:465–467PubMed
15.
go back to reference Heron E, Hernigou A, Chatellier G, Fornes P, Emmerich J, Fiessinger J (1999) Intracerebral calcification in systemic sclerosis. Stroke 30:2183–2185CrossRefPubMed Heron E, Hernigou A, Chatellier G, Fornes P, Emmerich J, Fiessinger J (1999) Intracerebral calcification in systemic sclerosis. Stroke 30:2183–2185CrossRefPubMed
16.
go back to reference Nagai Y, Sogabe Y, Ishikawa O (2008) Tumoral calcinosis of the ribs and lumbar spine in systemic sclerosis. Eur J Dermatol 18:473–474PubMed Nagai Y, Sogabe Y, Ishikawa O (2008) Tumoral calcinosis of the ribs and lumbar spine in systemic sclerosis. Eur J Dermatol 18:473–474PubMed
17.
go back to reference Teixeira M, Lima L, Costa J, de Figueirêdo L, Tapety C, do Rego S et al (2010) Calcinose distrófica de vulva em paciente com síndrome CREST. Acta Reumatol Port 35:264–266 Teixeira M, Lima L, Costa J, de Figueirêdo L, Tapety C, do Rego S et al (2010) Calcinose distrófica de vulva em paciente com síndrome CREST. Acta Reumatol Port 35:264–266
18.
go back to reference Alpöz E, Cankaya H, Güneri P (2007) Facial subcutaneous calcinosis and mandibular resorption in systemic sclerosis: a case report. Dentomaxillofac Radiol 36:172–174CrossRefPubMed Alpöz E, Cankaya H, Güneri P (2007) Facial subcutaneous calcinosis and mandibular resorption in systemic sclerosis: a case report. Dentomaxillofac Radiol 36:172–174CrossRefPubMed
19.
go back to reference Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755CrossRefPubMed Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755CrossRefPubMed
20.
go back to reference Le Roy EC, Black C, Fleischmajer R, Jablonska S, Krieg T et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205 Le Roy EC, Black C, Fleischmajer R, Jablonska S, Krieg T et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205
21.
go back to reference Furst DE, Clements PJ, Steen VD et al (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25:84–88PubMed Furst DE, Clements PJ, Steen VD et al (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25:84–88PubMed
22.
go back to reference Medsger T, Silman A, Steen V et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:59–67 Medsger T, Silman A, Steen V et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:59–67
23.
go back to reference Skare TL, Fonseca AE, Luciano AC, Azevedo PM (2011) Autoantibodies in scleroderma and their association with the clinical profile of the disease. A study of 66 patients from southern Brazil. Ann Bras Dermatol 86:1075–1081 Skare TL, Fonseca AE, Luciano AC, Azevedo PM (2011) Autoantibodies in scleroderma and their association with the clinical profile of the disease. A study of 66 patients from southern Brazil. Ann Bras Dermatol 86:1075–1081
24.
go back to reference Belloli L, Ughi N, Massarotti M, Marasini B, Biondi ML, Brambilla G (2010) Role of fetuin-A in systemic sclerosis-associated calcinosis. J Rheumatol 37:2638–2639CrossRefPubMed Belloli L, Ughi N, Massarotti M, Marasini B, Biondi ML, Brambilla G (2010) Role of fetuin-A in systemic sclerosis-associated calcinosis. J Rheumatol 37:2638–2639CrossRefPubMed
25.
go back to reference Aggarwal N, Shrestha S (2013) Dystrophic calcinosis cutis. N Engl J Med 368:21CrossRef Aggarwal N, Shrestha S (2013) Dystrophic calcinosis cutis. N Engl J Med 368:21CrossRef
26.
go back to reference Davies CA, Herrick AL, Cordingley L, Freemont AJ, Jeziorska M (2009) Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis. Rheumatology 48:876–882CrossRefPubMed Davies CA, Herrick AL, Cordingley L, Freemont AJ, Jeziorska M (2009) Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis. Rheumatology 48:876–882CrossRefPubMed
27.
go back to reference Schäfer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J et al (2003) The serum protein a2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112:357–366CrossRefPubMedPubMedCentral Schäfer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J et al (2003) The serum protein a2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112:357–366CrossRefPubMedPubMedCentral
28.
go back to reference Nitsche A (2012) Raynaud, úlceras digitales y calcinosis en esclerodermia. Reumatol Clin 8:270–277CrossRefPubMed Nitsche A (2012) Raynaud, úlceras digitales y calcinosis en esclerodermia. Reumatol Clin 8:270–277CrossRefPubMed
29.
go back to reference Robertson LP, Marshall RW, Hickling P (2003) Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 62:267–269CrossRefPubMedPubMedCentral Robertson LP, Marshall RW, Hickling P (2003) Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 62:267–269CrossRefPubMedPubMedCentral
30.
go back to reference Medina YF, Ortiz M, Barrera N, Chalem P, Motta A, Zamora F, Calvo E (2011) Relación de los anticuerpos anti-péptido citrulinado con manifestaciones osteo-articulares en una cohorte de pacientes con esclerodermia. Rev Colomb Reumatol 18(3):155–162 Medina YF, Ortiz M, Barrera N, Chalem P, Motta A, Zamora F, Calvo E (2011) Relación de los anticuerpos anti-péptido citrulinado con manifestaciones osteo-articulares en una cohorte de pacientes con esclerodermia. Rev Colomb Reumatol 18(3):155–162
31.
go back to reference Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23:617–625CrossRefPubMed Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23:617–625CrossRefPubMed
32.
go back to reference Reimer G, Steen VD, Penning CA, Medsger TA Jr, Tan EM (1988) Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 31:525–532CrossRefPubMed Reimer G, Steen VD, Penning CA, Medsger TA Jr, Tan EM (1988) Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 31:525–532CrossRefPubMed
33.
go back to reference Fritzler MJ, Kinsella MJ, Garbutt E (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526CrossRefPubMed Fritzler MJ, Kinsella MJ, Garbutt E (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526CrossRefPubMed
34.
go back to reference Steen VD, Lucas M, Fertig N, Medsger TA Jr (2007) Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol 34:2230–2235PubMed Steen VD, Lucas M, Fertig N, Medsger TA Jr (2007) Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol 34:2230–2235PubMed
35.
go back to reference Ceribelli A, Cavazzana I, Franceschini F, Airò P, Tincani A, Cattaneo R, Pauley BA, Chan EK, Satoh M (2010) Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 37:2071–2075CrossRefPubMed Ceribelli A, Cavazzana I, Franceschini F, Airò P, Tincani A, Cattaneo R, Pauley BA, Chan EK, Satoh M (2010) Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 37:2071–2075CrossRefPubMed
36.
go back to reference Zabek J, Palacz A, Pyka J, Krzewska I (2008) Antinucleolar antibodies in diagnostics of antiphospholipid syndrome. Pol Arch Med Wewn 118:25–30PubMed Zabek J, Palacz A, Pyka J, Krzewska I (2008) Antinucleolar antibodies in diagnostics of antiphospholipid syndrome. Pol Arch Med Wewn 118:25–30PubMed
37.
go back to reference Chander S, Gordon P (2012) Soft tissue and subcutaneous calcification in connective tissue diseases. Curr Opin Rheumatol 24:158–164CrossRefPubMed Chander S, Gordon P (2012) Soft tissue and subcutaneous calcification in connective tissue diseases. Curr Opin Rheumatol 24:158–164CrossRefPubMed
38.
go back to reference Lassoued K, Saiag P, Anglade MC, Roujeau JC, Touraine RL (1988) Failure of warfarin in treatment of calcinosis universalis. Am J Med 84:795–796CrossRefPubMed Lassoued K, Saiag P, Anglade MC, Roujeau JC, Touraine RL (1988) Failure of warfarin in treatment of calcinosis universalis. Am J Med 84:795–796CrossRefPubMed
39.
go back to reference Cukierman T, Elinav E, Korem M, Chajek-Shaul T (2004) Lowdose warfarin treatment for calcinosis in patients with systemic sclerosis. Ann Rheum Dis 63:1341–1343CrossRefPubMedPubMedCentral Cukierman T, Elinav E, Korem M, Chajek-Shaul T (2004) Lowdose warfarin treatment for calcinosis in patients with systemic sclerosis. Ann Rheum Dis 63:1341–1343CrossRefPubMedPubMedCentral
40.
go back to reference Ambler GR, Chaitow J, Rogers M, McDonald DW, Ouvrier RA (2005) Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 32:1837–1839PubMed Ambler GR, Chaitow J, Rogers M, McDonald DW, Ouvrier RA (2005) Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 32:1837–1839PubMed
41.
go back to reference Kalajian AH, Perryman JH, Callen JP (2009) Intravenous immunoglobulin therapy for dystrophic calcinosis cutis: unreliable in our hands. Arch Dermatol 145:334PubMed Kalajian AH, Perryman JH, Callen JP (2009) Intravenous immunoglobulin therapy for dystrophic calcinosis cutis: unreliable in our hands. Arch Dermatol 145:334PubMed
42.
go back to reference Sparsa A, Lesaux N, Kessler E, Bonnetblanc JM, Blaise S, Lebrun-Ly V, Colombeau P, Vidal E, Bédane C (2005) Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy. J Am Acad Dermatol 53:263–265CrossRef Sparsa A, Lesaux N, Kessler E, Bonnetblanc JM, Blaise S, Lebrun-Ly V, Colombeau P, Vidal E, Bédane C (2005) Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy. J Am Acad Dermatol 53:263–265CrossRef
43.
go back to reference Chamberlain AJ, Walker NP (2003) Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbon dioxide laser. Dermatol Surg 29:968–970PubMed Chamberlain AJ, Walker NP (2003) Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbon dioxide laser. Dermatol Surg 29:968–970PubMed
44.
go back to reference Meissner M, Ochsendorf F, Kaufmann R (2010) Therapy of calcinosis cutis using erbium-doped yttrium aluminum garnet laser treatment. Dermatol Surg 36:727–728CrossRefPubMed Meissner M, Ochsendorf F, Kaufmann R (2010) Therapy of calcinosis cutis using erbium-doped yttrium aluminum garnet laser treatment. Dermatol Surg 36:727–728CrossRefPubMed
45.
go back to reference Merlino G, Germano S, Carlucci S (2013) Surgical management of digital calcinosis in CREST syndrome. Aesth Plast Surg 37:1214–1219CrossRef Merlino G, Germano S, Carlucci S (2013) Surgical management of digital calcinosis in CREST syndrome. Aesth Plast Surg 37:1214–1219CrossRef
Metadata
Title
Clinical, biochemical, and radiological characterization of the calcinosis in a cohort of Mexican patients with systemic sclerosis
Authors
María Pilar Cruz-Domínguez
Grettel García-Collinot
Miguel A. Saavedra
Gabriela Medina
Rosa Angélica Carranza-Muleiro
Olga Lidia Vera-Lastra
Luis J. Jara
Publication date
01-01-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 1/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3412-9

Other articles of this Issue 1/2017

Clinical Rheumatology 1/2017 Go to the issue